LOGIN
ID
PW
MemberShip
2025-07-15 05:44
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Company
Omjjara¡¯s reimbursement progress gains attention
by
Eo, Yun-Ho
Jul 14, 2025 06:04am
Attention is turning to whether progress will be made in the reimbursement listing process for the new myelofibrosis drug, Omjjara. Omjjara (momelotinib), a myelofibrosis treatment developed by GSK Korea, passed the Health Insurance Review and Assessment Service's Cancer Disease Review Committee in March and is currently awaiting submissi
Company
Aftermath of Januvia's price cut¡¦MSD-CKD compensation fight
by
Son, Hyung Min
Jul 14, 2025 06:04am
Regarding transaction for price difference compensation following the drug price reduction for the diabetes treatment Januvia, Chong Kun Dang and MSD Korea have not reached agreement during negotiation for nearly two years. While the distribution industry continues to demand compensation for losses incurred due to the drug price cut, the lac
Company
Daiichi Sankyo and Ono Pharmaceutical see surge in sales
by
Son, Hyung Min
Jul 14, 2025 06:03am
Japanese pharmaceutical companies operating in South Korea saw overall sales growth last year. All seven companies surveyed achieved year-on-year sales growth, with Daiichi Sankyo Korea and Ono Pharma Korea leading the way with double-digit growth rates. However, in terms of operating profits, the companies showed mixed emotions. According to
Company
Bimzelx may be prescribed at general hospitals in KOR
by
Eo, Yun-Ho
Jul 11, 2025 06:12am
The new psoriasis drug Bimzelx may be prescribed at general hospitals in Korea. According to industry sources, UCB Pharma Korea's Bimzelx (bimekizumab) has been approved by the Drug Committees (DCs) of major hospitals nationwide, including tertiary hospitals like Seoul Asan Medical Center and Severance Hospital as well as major hospitals
Company
Gastric cancer-targeted therapy 'Vyloy' seeks reimb again
by
Eo, Yun-Ho
Jul 10, 2025 06:10am
Vyloy, a gastric cancer-targeted therapy, is once again vying for inclusion in the National Health Insurance reimbursement list. According to industry sources, Astellas Pharma Korea recently submitted a reimbursement application for Vyloy (zolbetuximab), a targeted treatment for Claudin 18.2-positive gastric cancer. Vyloy did not pass
Company
Ono Pharma Korea¡¯s sales double in 4 years with Opdivo
by
Son, Hyung Min
Jul 10, 2025 06:09am
Ono Pharmaceutical Korea continued its sales growth, powered by its immuno-oncology drug Opdivo. The company's sales doubled in 4 years. The company is preparing for the expiration of Opdivo's patent by securing a diverse pipeline of new anticancer drugs, including antibody-drug conjugates (ADCs) and novel immuno-oncology drugs with different me
Company
Credit ratings for Samsung Biologics¡¤JW Holdings¡è
by
Kim, Jin-Gu
Jul 10, 2025 06:08am
Major pharmaceutical and biotech companies (biopharma companies) are facing varying differing credit ratings and outlooks. While Samsung Biologics and JW Holdings received upward credit ratings, Handok was downgraded. Dong-A ST's credit rating outlook shifted from 'stable' to 'negative'. Credit rating agencies explained that these resul
Company
'Ebglyss' can be prescribed at general hospitals
by
Eo, Yun-Ho
Jul 9, 2025 06:10am
'Ebglyss,' a new drug for the treatment of atopic dermatitis, is now available for prescription at general hospitals. According to industry sources, Lily Korea's interleukin (IL)-13 inhibitor 'Ebglyss (lebrikizumab)' has passed the drug committees (DC) of tertiary general hospitals, including Seoul National University Hospital, Asan Medic
Company
Adding amiloride effective in resistant hypertension
by
Son, Hyung Min
Jul 9, 2025 06:08am
A new treatment option has been proposed for patients with resistant hypertension that cannot be controlled even with the existing triple combination therapy for hypertension. A regimen combining an olmesartan-based triple combination therapy with the potassium-sparing diuretic ¡®amiloride¡¯ demonstrated similar blood pressure-lowering effec
Company
Novo Nordisk's injectables are in short supply
by
Nho, Byung Chul
Jul 8, 2025 06:35am
Novo Nordisk's diabetes insulin injections are experiencing a short-term shortage, causing supply difficulties in prescribing settings in Korea. The products with limited supply include NovoRapid Flexpen¡¤Novomix Flexpen¡¤Levemir Flexpen. Novo Nordisk sent a notice to distributors, pharmacies, hospitals, and clinics late last month, inf
1
2
3
4
5
6
7
8
9
10
>